Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ganten

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Hepatology (Baltimore, Md.)|June 18, 2005
Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cellsKerstin Herzer, Tom M Ganten, Henning Schulze-Bergkamen, et al.
Langenbeck'S Archives of Surgery|October 5, 2013
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantationJan Pfeiffenberger, Ronald Koschny, Katrin Hoffmann, et al.
Cancer Genetics and Cytogenetics|October 24, 2007
Cytogenetic and molecular biological characterization of an adult medulloblastomaHeidrun Holland, Ronald Koschny, Wolfgang Krupp, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic windowRonald Koschny, Tom M Ganten, Jaromir Sykora, et al.
Annals of Transplantation|November 2, 2016
Impact of Inter-Laboratory Variability on Model of End-Stage Liver Disease (MELD) Score CalculationMohammed Al-Saeedi, Taha Yassein, Daniel Schultze, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 15, 2009
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancerTom M Ganten, Jaromir Sykora, Ronald Koschny, et al.
British Journal of Clinical Pharmacology|June 19, 2013
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scoresAlbader Albarmawi, David Czock, Annika Gauss, et al.
Clinical Transplantation|April 27, 2011
Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysisKatrin Hoffmann, Ulf Hinz, Norbert Hillebrand, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 14, 2009
Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest GermanyS Brost, J J Wenzel, T M Ganten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2017
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT StudyTom M Ganten, Rudolf E Stauber, Eckardt Schott, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|June 18, 2005
Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cellsKerstin Herzer, Tom M Ganten, Henning Schulze-Bergkamen, et al.
Langenbeck'S Archives of Surgery|October 5, 2013
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantationJan Pfeiffenberger, Ronald Koschny, Katrin Hoffmann, et al.
Cancer Genetics and Cytogenetics|October 24, 2007
Cytogenetic and molecular biological characterization of an adult medulloblastomaHeidrun Holland, Ronald Koschny, Wolfgang Krupp, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic windowRonald Koschny, Tom M Ganten, Jaromir Sykora, et al.
Annals of Transplantation|November 2, 2016
Impact of Inter-Laboratory Variability on Model of End-Stage Liver Disease (MELD) Score CalculationMohammed Al-Saeedi, Taha Yassein, Daniel Schultze, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 15, 2009
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancerTom M Ganten, Jaromir Sykora, Ronald Koschny, et al.
British Journal of Clinical Pharmacology|June 19, 2013
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scoresAlbader Albarmawi, David Czock, Annika Gauss, et al.
Clinical Transplantation|April 27, 2011
Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysisKatrin Hoffmann, Ulf Hinz, Norbert Hillebrand, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 14, 2009
Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest GermanyS Brost, J J Wenzel, T M Ganten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2017
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT StudyTom M Ganten, Rudolf E Stauber, Eckardt Schott, et al.
Pageof 5